Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Choosing a safe browser for crypto requires weighing security features and privacy controls. This intro provides a practical starting point.
20,598 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A practical look at a top energy stock evolving at the crossroads of renewables and AI. Learn how to assess the setup...
A significant share of women say their gender slows their progress, affecting careers and money. Learn practical stra...
Investors are buzzing about a SpaceX and TESLA merger. This piece dives into what a deal could mean for AI, energy, a...
An insurer’s blockbuster profit alongside an insider stock sale creates a compelling investing puzzle. This article b...
A notable market strength conflicts with a warning signal rarely seen outside the dot-com era. This article explains ...
Strong friendships among women go beyond looks and style. This article explores what women appreciate most in each ot...
As AI reshapes markets, critics say consumer data funds the surge while a handful of platforms claim the profits. Thi...
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...
Space investors are watching SpaceX's stock swing as it moves from early enthusiasm to a more tempered pullback. This...
A 5% pullback in the Nasdaq in 2026 echoes big past moves and offers clues about which stocks tend to fare best durin...
SK Hynix's $29 billion ADR listing becomes a live test of whether the memory cycle can endure. Markets will parse dem...